MD
Departments of Infectious Diseases, Infection Control and Employee Health, and Gastroenterology, Hepatology and Nutrition
Disclosure: Merck & Co., Inc. (Grant/Research Support)
Harrys A. Torres, MD, FACP, FIDSA, is an Associate Professor of Medicine in the Department of Infectious Diseases, Infection Control and Employee Health and an Adjunct Associate Professor, Department of Gastroenterology, Hepatology, and Nutrition at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is board-certified in internal medicine, and infectious disease, with additional accreditations on HIV/AIDS and Tropical Medicine and Hygiene. He is the founder and director of the Hepatitis C virus (HCV) clinic at MD Anderson, the first established clinic in the US, and likely in the world, devoted to managing HCV in cancer patients.
Dr. Torres is a member of numerous national committees for professional societies such as the Infectious Diseases Society of America, the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver, and the American Society for Blood and Marrow Transplantation. His research interest is to facilitate translational research in the prevention, detection, and treatment of HCV in patients with cancer and hematopoietic cell transplantation.
Dr. Torres is co-author of more than 100 articles published in peer-reviewed journals, including CA: A Cancer Journal for Clinicians, Gastroenterology, Hepatology, Journal of Hepatology, Journal of the National Cancer Institute, Lancet Haematology, American Journal of Gastroenterology, Leukemia, Clinical Infectious Diseases, Blood, and Nature Reviews Clinical Oncology. He has presented almost 130 abstracts in international meetings and written 8 book chapters. His work on HCV has been awarded multiple times by the AASLD and American Society of Clinical Oncology among others. Dr. Torres trains infectious diseases and gastroenterology fellows in the diagnosis and management of HCV in this special patient population. By providing evidence and innovative approaches, his body of work has changed the standard of care for HCV-infected cancer patients.
